Epidemiological risk factors for hypersensitivity reactions to abacavir*
- 3 October 2003
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 4 (4), 321-324
- https://doi.org/10.1046/j.1468-1293.2003.00166.x
Abstract
We investigated risk factors for hypersensitivity reactions (HSR) to abacavir in a case–control study. In a multivariate analysis, white race [odds ratio (OR), 5.16; 95% confidence interval (CI), 1.16–22.97] and a higher CD8 cell count at initiation of abacavir (>850 vs. ≤850 cells: OR, 3.74; 95% CI, 1.19–11.77) were found to be significantly associated with the development of HSR. Age, gender, stage of disease, prior antiretroviral exposure and type of concurrent antiretroviral therapy were not associated with HSR. Differences in predisposition to HSR according to ethnicity and baseline CD8 cell count may be explained by the reported MHC genetic associations with HSR.Keywords
This publication has 6 references indexed in Scilit:
- Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rashAIDS, 2002
- Association between presence of HLA-B*5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirThe Lancet, 2002
- Genetic variations in HLA-B region and hypersensitivity reactions to abacavirThe Lancet, 2002
- Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavirClinical Therapeutics, 2001
- Sex Differences in Nevirapine RashClinical Infectious Diseases, 2001
- Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adultsAIDS, 1998